ClinicalTrials.gg
RecruitingNCT07813468BT-HC034S-101Updated Nov 4, 2026

A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects

A Phase 1 interventional study of HC034S and Erbitux (Cetuximab) in Cetuximab, Bioequivalence and Healthy Volunteers, sponsored by HC Biopharma Inc.. Recruiting at 1 site in China. Open to male participants aged 18 Years to 46 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by HC Biopharma Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 4, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 46 Years
Sex
Male
01

Study summary

A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection versus Erbitux in Healthy Male Subjects

02

Conditions studied

  • Cetuximab
  • Bioequivalence
  • Healthy Volunteers
  • Pharmacokinetics
03

In context

Lead sponsor

HC Biopharma Inc. is the lead sponsor of 9 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 46 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Provide written prior to study entry and fully understand the study content, procedures and potential adverse reactions;
  2. Be able to complete the study as required by the study protocol;
  3. Have no fertility plan (including sperm donation) in the subsequent 6 months and agree to use effective ;
  4. Be healthy male subjects aged 18-46 years (inclusive); body weight ≥50 kg; (BMI, calculated as weight [kg]/height² [m²]) ranging from 18.0 to 28.5 kg/m² (inclusive).

Exclusion Criteria:

  1. Provide written informed consent prior to study entry and fully understand the study content, procedures and potential adverse reactions;
  2. Be able to complete the study as required by the study protocol;
  3. Have no fertility plan (including sperm donation) in the subsequent 6 months and agree to use effective contraception;
  4. Be healthy male subjects aged 18-46 years (inclusive); body weight ≥50 kg; body mass index (BMI, calculated as weight [kg]/height² [m²]) ranging from 18.0 to 28.5 kg/m² (inclusive).

Exclusion Criteria:

  1. Subjects with allergic diathesis, or history of food/drug allergy within recent 4 weeks, especially to any component of product or ;
  2. Blood donation or substantial blood loss (>200 mL) within 3 months, or donation within 2 weeks prior to investigational product administration;
  3. Major surgery within 6 months prior to first dosing, or planned surgery during study;
  4. Hereditary bleeding tendency, coagulation disorders, or history of thrombosis / hemorrhagic diseases;
  5. Prior treatment with EGFR-targeted agents;
  6. Use of prescription / over-the-counter drugs or nutritional supplements within 5 half-lives of the product OR within 2 weeks before study drug administration (whichever is longer). Discontinue traditional Chinese medicinal supplements 28 days prior to study drug administration, except for topical products with no systemic absorption.
  7. abnormalities as assessed by investigator in vital signs (SBP \<90 mmHg or >140 mmHg; DBP >90 mmHg), physical examination, (resting heart rate \<50 or >100 beats/min), laboratory tests (blood biochemistry, CBC, urinalysis, coagulation);
  8. Presence of any investigator-identified clinically significant disease, including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immune, psychiatric, cardiovascular and cerebrovascular disorders;
  9. History of , , AIDS, syphilis, or clinically significant abnormality in ≥1 item of infectious disease four-panel screening;
  10. Alcohol intake ≥14 units/week within 3 months pre-screening (1 unit = 285 mL beer, 25 mL 40%-ABV spirits, 150 mL 12%-ABV wine); alcohol-containing products consumed within 24 h prior to study drug dosing; positive alcohol breath test at screening;
  11. Cigarette smoking ≥5 cigarettes/day within 3 months pre-screening;
  12. Drug abuse history within 5 years, illicit drug use within 3 months before screening, habitual use of any medicines (including herbal medicines), or positive urine drug screen.
  13. Participation in any drug clinical trial with investigational product administration, or medical device trial receiving device treatment, or use of drugs of the same class within 3 months prior to screening;
  14. Receipt of within 14 days prior to first dosing, or planned live-attenuated vaccination during study;
  15. Intolerance to venipuncture blood collection, or history of needle-phobia or hematophobia;
  16. Any subject who, in investigator's judgment, may be unable to provide informed consent or follow the protocol; whose participation may bias study results or endanger subject safety; or otherwise considered unsuitable for study enrollment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    HC034S

    Drug: HC034S

  • Active comparator
    China-sourced Erbitux®

    Drug: Erbitux (Cetuximab)

Interventions

  • DrugHC034S

    Single intravenous infusion. Study participants shall be pre-medicated with antihistamines and corticosteroids no less than 1 h before the first HC034S injection infusion. Administer intravenously by infusion pump at 250 mg/m² (body surface area), infusion duration: 2 h ± 10 min.

  • Single intravenous infusion. Study participants shall be pre-medicated with antihistamines and corticosteroids no less than 1 h before the first cetuximab injection infusion. Administer intravenously by infusion pump at 250 mg/m² (body surface area), infusion duration: 2 h ± 10 min.

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve from time 0 to infinity (AUC0-∞)

    Time frame: Up to Day 29

Secondary outcomes

  1. quantifiable concentration (AUC₀-t)

    Time frame: Up to Day 29

  2. Maximum serum concentration (Cmax)

    Time frame: Up to Day 29

  3. Time to reach maximum serum concentration (Tmax)

    Time frame: Up to Day 29

  4. Total clearance (CL)

    Time frame: Up to Day 29

  5. Terminal elimination half-life (t1/2)

    Time frame: Up to Day 29

  6. Apparent volume of distribution (Vd)

    Time frame: Up to Day 29

  7. Apparent terminal elimination rate constant (λz)

    Time frame: Up to Day 29

  8. Percentage of the area-under-the-curve extrapolated to infinity (AUC_%Extrap)

    Time frame: Up to Day 29

  9. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) following study drug administration, including electrocardiograms (ECG), laboratory test parameters, physical examinations, and vital signs.

    Time frame: Up to Day 29

  10. Positive incidence, titer and duration of anti-drug antibodies (ADA) and neutralizing antibodies (NAb)

    Time frame: Up to Day 29

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2026
First posted
Sep 10, 2026
StartActual
Sep 12, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 5, 2026→Sep 12, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Start date Sep 5, 2026→Sep 12, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07813468
Lead sponsor
HC Biopharma Inc.
Responsible party
Sponsor
First posted
Sep 10, 2026
Start date
Sep 12, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Xiaoai He
Contact
15008971099@126.com
+86-1500-897-1099

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion